Ultragenyx Pharmaceutical (NASDAQ:RARE) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other research firms have also weighed in on RARE. Morgan Stanley restated an “equal weight” rating and set a $71.00 target price (up previously from $69.00) on shares of Ultragenyx Pharmaceutical in a report on Friday, October 6th. Robert W. Baird restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 19th. Jefferies Group upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and upped their target price for the stock from $58.00 to $72.00 in a report on Monday, December 4th. Barclays upped their target price on Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 5th. Finally, Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 12th. Ten analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $72.40.

Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down $0.19 during trading on Friday, reaching $50.81. The company’s stock had a trading volume of 374,946 shares, compared to its average volume of 388,979. The stock has a market capitalization of $2,172.04, a price-to-earnings ratio of -7.29 and a beta of 1.83. Ultragenyx Pharmaceutical has a one year low of $43.14 and a one year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.87). The company had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.02 million. The firm’s quarterly revenue was up 81.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.64) EPS. equities research analysts predict that Ultragenyx Pharmaceutical will post -7.3 EPS for the current year.

Several hedge funds have recently modified their holdings of the company. Capital Research Global Investors increased its position in shares of Ultragenyx Pharmaceutical by 1.4% during the second quarter. Capital Research Global Investors now owns 5,183,330 shares of the biopharmaceutical company’s stock worth $321,937,000 after purchasing an additional 71,811 shares in the last quarter. BlackRock Inc. increased its position in shares of Ultragenyx Pharmaceutical by 10.4% during the second quarter. BlackRock Inc. now owns 3,497,591 shares of the biopharmaceutical company’s stock worth $217,237,000 after purchasing an additional 330,911 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Ultragenyx Pharmaceutical by 4.5% during the second quarter. Vanguard Group Inc. now owns 3,130,273 shares of the biopharmaceutical company’s stock worth $194,421,000 after purchasing an additional 135,335 shares in the last quarter. Capital International Investors increased its position in shares of Ultragenyx Pharmaceutical by 21.9% during the third quarter. Capital International Investors now owns 2,895,481 shares of the biopharmaceutical company’s stock worth $154,213,000 after purchasing an additional 520,496 shares in the last quarter. Finally, State Street Corp increased its position in shares of Ultragenyx Pharmaceutical by 21.4% during the second quarter. State Street Corp now owns 1,536,285 shares of the biopharmaceutical company’s stock worth $95,417,000 after purchasing an additional 270,729 shares in the last quarter. 94.10% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/06/ultragenyx-pharmaceutical-rare-upgraded-by-bidaskclub-to-hold.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.